Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly is paying Shanghai-based Junshi Biosciences $10 million upfront for the rights outside Greater China to JS016, a neutralizing monoclonal antibody…
The U.S. FDA granted emergency use authorization to Regeneron's casirivimab and imdevimab antibody cocktail for high-risk outpatients with mild-to-moderate…
As of the end of the public health emergency declaration on May 11, 2023, the Centers for Disease Control and Prevention reported approximately 104 million…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Eli Lilly and Junshi Biosciences entered a co-development agreement for SARS-CoV-2 neutralizing antibodies (lead JS016, later named etesevimab) for COVID-19 prevention and treatment. Lilly paid $10M upfront with up to $245M in milestones and double-digit royalties; Lilly secured exclusive rights ex-Greater China while Junshi retained Greater China rights. Lilly also committed to a $75M conditional Junshi share subscription.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Shanghai Junshi Biosciences Co., Ltd. (this deal) | 2020 | $255M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2020 deals · Eli Lilly and Company deals · Vaccines deals